These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26630041)

  • 1. Mesalamine Intolerance in Three Children with Crohn's Disease.
    Tuna Kirsaclioglu C; Kuloglu Z; Ustundag G; Kansu A; İnce E; Ensari A; Girgin N
    Med Princ Pract; 2016; 25(3):293-5. PubMed ID: 26630041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesalazine-induced Churg-Strauss syndrome in a patient with Crohn's disease and sclerosing cholangitis.
    Sinico RA; Sabadini E; Maresca AM
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S104. PubMed ID: 16859609
    [No Abstract]   [Full Text] [Related]  

  • 3. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalamine-induced myopericarditis in a paediatric patient with Crohn's disease.
    Nair AG; Cross RR
    Cardiol Young; 2015 Apr; 25(4):783-6. PubMed ID: 24915235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalamine-induced myocarditis following diagnosis of Crohn's disease: a case report.
    Galvão Braga C; Martins J; Arantes C; Ramos V; Vieira C; Salgado A; Magalhães S; Correia A
    Rev Port Cardiol; 2013 Sep; 32(9):717-20. PubMed ID: 23993290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial nephritis in children with Crohn's disease.
    Benador N; Grimm P; Lemire J; Griswold W; Billman G; Reznik V
    Clin Pediatr (Phila); 2000 Apr; 39(4):253-4. PubMed ID: 10791141
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts.
    Lichtenstein GR; Cuffari C; Kane SV; Hanauer S; Present DH
    Inflamm Bowel Dis; 2004 Jul; 10 Suppl 2():S11-21. PubMed ID: 15475769
    [No Abstract]   [Full Text] [Related]  

  • 11. [Angioedema in Crohn's disease possibly due to mesalazine].
    Nguyen-Khac E; Le Baron F; Thevenot T; Tiry-Lescut C; Tiry F
    Gastroenterol Clin Biol; 2002 May; 26(5):535-6. PubMed ID: 12122371
    [No Abstract]   [Full Text] [Related]  

  • 12. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE; Hanauer SB
    Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
    Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
    Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inflammatory diseases of the intestines].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
    Kamm MA
    Inflamm Bowel Dis; 2005 Jun; 11(6):616-7. PubMed ID: 15905712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.
    Cammà C; Giunta M; Rosselli M; Cottone M
    Gastroenterology; 1997 Nov; 113(5):1465-73. PubMed ID: 9352848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine-induced psoriasis in patients with inflammatory bowel diseases.
    Di Cesare A; Fidanza R; Riitano A; Fargnoli MC; Peris K
    Eur J Dermatol; 2011; 21(5):784-5. PubMed ID: 21697068
    [No Abstract]   [Full Text] [Related]  

  • 20. Does the initial location of Crohn's disease have an influence on the time-to-relapse in patients under maintenance treatment with oral mesalamine?
    Bresci G; Parisi G; Bertoni M; Masolino P; Scatena F; Capria A
    J Clin Gastroenterol; 2000 Sep; 31(2):147-51. PubMed ID: 10993432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.